-
公开(公告)号：US20130012521A1
公开(公告)日：2013-01-10
申请号：US13618841
申请日：2012-09-14
IPC分类号： A61K31/4439 , C07D471/04 , A61K31/444 , A61K31/4709 , A61K31/4545 , A61K31/496 , A61K31/506 , A61P9/00 , A61P3/10 , A61P13/12 , A61P11/00 , A61P1/16 , A61P25/28 , A61P29/00 , C07D401/14
CPC分类号： A61K31/444 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/585 , A61K45/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/048
摘要： The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
摘要翻译： 本发明涉及式（I）的化合物：其中X 1，X 2，X 3，X 4，X 5，X 6，X 7，X 8，R 1，R 2，R 3如上所定义。 该化合物具有凋亡信号调节激酶（ASK1）抑制活性，因此可用于治疗ASK1介导的病症，包括自身免疫疾病，炎性疾病，心血管疾病和神经变性疾病。 本发明还涉及包含一种或多种式（I）化合物的药物组合物和制备式（I）化合物的方法。
-
公开(公告)号：US20110135594A1
公开(公告)日：2011-06-09
申请号：US12997487
申请日：2009-07-14
IPC分类号： A61K31/404 , C07D209/34 , C07D413/12 , C07D417/10 , C07D403/10 , C07D405/10 , C07D513/04 , C07D409/14 , C07D413/14 , C07D417/14 , A61K31/5377 , A61K31/427 , A61K31/4178 , A61K31/496 , A61K31/429 , A61K31/675 , A61K33/24 , A61K31/519 , A61K31/52 , A61K31/513 , A61K31/7068 , A61K31/704 , A61K38/12 , A61K38/50 , A61K39/395 , A61K38/19 , A61P35/00 , A61P3/00 , A61P37/06 , A61P3/10 , A61P25/00 , A61P25/28 , A61P11/00 , A61P19/04 , A61P13/12 , A61P35/02
CPC分类号： C07D209/34 , C07D407/10 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/04 , C07D513/04
摘要： A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. (Formula should be inserted here) Formula (I)
摘要翻译： 具有组蛋白脱乙酰酶（HDAC）和/或CDK抑制活性的通式（I）的化合物，包含该化合物的药物组合物和可用于使用该化合物治疗疾病的方法。 （公式应在此插入）公式（I）
-
公开(公告)号：US20070054864A1
公开(公告)日：2007-03-08
申请号：US11478337
申请日：2006-06-28
CPC分类号： A61K38/05 , C07K5/06034
摘要： The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
摘要翻译： 本发明涉及作为抗病毒剂的化合物。 具体地说，本发明的化合物抑制HCV的复制，因此可用于治疗丙型肝炎感染。 本发明还涉及包含这些化合物的药物组合物及其制备方法。
-
公开(公告)号：US08673966B2
公开(公告)日：2014-03-18
申请号：US13599368
申请日：2012-08-30
IPC分类号： C07D311/36 , A61K31/353 , A61P25/30
CPC分类号： C07D311/36 , C07D405/06 , C07D405/10
摘要： Disclosed are novel isoflavone derivatives having the structure of Formula I: which are ALDH-2 inhibitors, useful for treating a patient in need thereof, for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.
摘要翻译： 公开了具有式I结构的新型异黄酮衍生物：其是用于治疗有需要的患者的依赖于成瘾药物的ALDH-2抑制剂，例如对多巴胺产生剂如可卡因，吗啡，安非他明 ，尼古丁和酒精。
-
公开(公告)号：US08598360B2
公开(公告)日：2013-12-03
申请号：US13618841
申请日：2012-09-14
IPC分类号： A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4545 , A61K31/496 , A61K31/506 , A61P9/00 , A61P3/10 , A61P13/12 , A61P11/00 , A61P1/16 , A61P25/28 , A61P29/00 , C07D401/14 , C07D471/04
CPC分类号： A61K31/444 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/585 , A61K45/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/048
摘要： The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
摘要翻译： 本发明涉及式（I）的化合物：其中X 1，X 2，X 3，X 4，X 5，X 6，X 7，X 8，R 1，R 2，R 3如上所定义。 该化合物具有凋亡信号调节激酶（“ASK1”）抑制活性，因此可用于治疗ASK1介导的病症，包括自身免疫性疾病，炎性疾病，心血管疾病和神经变性疾病。 本发明还涉及包含一种或多种式（I）化合物的药物组合物和制备式（I）化合物的方法。
-
公开(公告)号：US08431610B2
公开(公告)日：2013-04-30
申请号：US13563068
申请日：2012-07-31
IPC分类号： C07D207/08 , A61K31/4025
CPC分类号： C07C271/22 , A61K31/40 , A61K31/4015 , A61K31/4025 , A61K31/475 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/52 , A61K31/5375 , A61K31/5377 , A61K31/573 , A61K31/655 , A61K31/661 , A61K31/704 , A61K31/7068 , C07D207/27 , C07D211/76 , C07D295/108 , C07D295/125 , C07D333/46
摘要： The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
摘要翻译： 本发明提供具有组蛋白脱乙酰酶（HDAC）抑制活性的通式（I）的化合物，包含该化合物的药物组合物和可用于使用该化合物治疗疾病的方法。
-
公开(公告)号：US08378108B2
公开(公告)日：2013-02-19
申请号：US12834673
申请日：2010-07-12
IPC分类号： A61K31/444 , A61K31/4439 , A61K31/496 , A61K31/506 , A61K31/4725 , A61K31/437 , A61K31/5377 , C07D401/14 , C07D401/12 , C07D471/04 , C07D413/14 , A61P37/00 , A61P25/28 , A61P9/00
CPC分类号： A61K31/444 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/585 , A61K45/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/048
摘要： The present invention relates to compounds of Formula (I): where in X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
摘要翻译： 本发明涉及式（I）化合物：其中X 1，X 2，X 3，X 4，X 5，X 6，X 7，X 8，R 1，R 2，R 3如上所定义。 该化合物具有凋亡信号调节激酶（ASK1）抑制活性，因此可用于治疗ASK1介导的病症，包括自身免疫疾病，炎性疾病，心血管疾病和神经变性疾病。 本发明还涉及包含一种或多种式（I）化合物的药物组合物和制备式（I）化合物的方法。
-
公开(公告)号：US08088771B2
公开(公告)日：2012-01-03
申请号：US12510809
申请日：2009-07-28
IPC分类号： A61K31/5377 , A61K31/4178 , A61K31/4965 , A61K31/497 , C07D405/14 , C07D417/14
CPC分类号： C07D471/04 , C07D213/56 , C07D277/24 , C07D277/30 , C07D277/56 , C07D277/60 , C07D405/04 , C07D405/14 , C07D409/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D513/04
摘要： The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
-
公开(公告)号：US20090005374A1
公开(公告)日：2009-01-01
申请号：US12146894
申请日：2008-06-26
IPC分类号： A61K31/5377 , C07D471/04 , C07D413/14 , A61K31/437 , A61P35/00 , A61K31/497 , C07D401/14
CPC分类号： C07D471/04
摘要： A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
摘要翻译： 具有组蛋白脱乙酰酶（HDAC）和/或CDK抑制活性的通式（I）的化合物，包含该化合物的药物组合物和可用于使用该化合物治疗疾病的方法。
-
公开(公告)号：US20070105892A1
公开(公告)日：2007-05-10
申请号：US10583629
申请日：2004-12-22
申请人： Michael Graupe , Agnes Lau , Jiayao Li , John Link , Craig Mossman , Soon H. Woo , Sheila M. Zipfel
发明人： Michael Graupe , Agnes Lau , Jiayao Li , John Link , Craig Mossman , Soon H. Woo , Sheila M. Zipfel
IPC分类号： A61K31/4745 , A61K31/4245 , C07D491/02 , C07D271/10
CPC分类号： C07D417/14 , C07D263/56 , C07D271/06 , C07D413/12 , C07D417/12 , C07D498/04
摘要： The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
摘要翻译： 本发明涉及半胱氨酸蛋白酶，特别是组织蛋白酶B，K，L，F和S的抑制剂的化合物，因此可用于治疗由这些蛋白酶介导的疾病。 本发明涉及包含这些化合物的药物组合物及其制备方法。
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.12 秒)
